Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 2
2013 1
2014 1
2015 3
2016 2
2017 3
2019 2
2020 2
2021 1
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
P90 ribosomal S6 kinases: A bona fide target for novel targeted anticancer therapies?
Koutsougianni F, Alexopoulou D, Uvez A, Lamprianidou A, Sereti E, Tsimplouli C, Ilkay Armutak E, Dimas K. Koutsougianni F, et al. Biochem Pharmacol. 2023 Apr;210:115488. doi: 10.1016/j.bcp.2023.115488. Epub 2023 Mar 7. Biochem Pharmacol. 2023. PMID: 36889445 Review.
Interestingly, increased expression of RSKs has also been demonstrated in various cancers, such as breast, prostate, and lung cancer. This review aims to present the most recent advances in the field of RSK signaling that have occurred, such as biological insights, functio …
Interestingly, increased expression of RSKs has also been demonstrated in various cancers, such as breast, prostate, and lung cancer. …
Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers.
Pagni F, Guerini-Rocco E, Schultheis AM, Grazia G, Rijavec E, Ghidini M, Lopez G, Venetis K, Croci GA, Malapelle U, Fusco N. Pagni F, et al. Int J Mol Sci. 2019 Nov 1;20(21):5452. doi: 10.3390/ijms20215452. Int J Mol Sci. 2019. PMID: 31683784 Free PMC article. Review.
In this review, we provide an overview of the role of these biomarkers and their characterization in the management of lung cancer, melanoma, colorectal cancer, gastric cancer, head and neck cancer, renal cell carcinoma, urothelial cancers, and breast cancer....
In this review, we provide an overview of the role of these biomarkers and their characterization in the management of lung cancer, melanoma …
PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
Ivanova M, Frascarelli C, Cerbelli B, Pignataro MG, Pernazza A, Venetis K, Sajjadi E, Criscitiello C, Curigliano G, Guerini-Rocco E, Graziano P, Martini M, d'Amati G, Fusco N. Ivanova M, et al. Hum Pathol. 2024 Feb;144:22-27. doi: 10.1016/j.humpath.2024.01.008. Epub 2024 Jan 24. Hum Pathol. 2024. PMID: 38278450
Several factors make this test challenging in metastatic triple-negative breast cancer (mTNBC). Different assays and platforms are available, each associated with distinct scoring systems and threshold values specific to the ICI compound used, i.e. ...The IC with SP142 was …
Several factors make this test challenging in metastatic triple-negative breast cancer (mTNBC). Different assays and platforms are av …
Stimuli-Responsive Hydrogel Microcapsules Harnessing the COVID-19 Immune Response for Cancer Therapeutics.
Fischer A, Ehrlich A, Plotkin Y, Ouyang Y, Asulin K, Konstantinos I, Fan C, Nahmias Y, Willner I. Fischer A, et al. Angew Chem Int Ed Engl. 2023 Oct 23;62(43):e202311590. doi: 10.1002/anie.202311590. Epub 2023 Sep 19. Angew Chem Int Ed Engl. 2023. PMID: 37675854
We present the development of stimuli-responsive microcapsules, loaded with a viral immunogenetic agent, harnessing the immune response against the Coronavirus Disease 2019, COVID-19, to selectively attack liver cancer cells (hepatoma) or recognize breast cancer or hepatom …
We present the development of stimuli-responsive microcapsules, loaded with a viral immunogenetic agent, harnessing the immune response agai …
Brain and bone marrow metastases from rectal cancer.
Thomopoulou K, Manolakou S, Messaritakis I, Tzardi M, Lagoudaki E, Koutsopoulos A, Koulouris A, Kanellis G, Kalbakis K, Mavroudis D, Souglakos I. Thomopoulou K, et al. Ann Gastroenterol. 2020 Jan-Feb;33(1):95-97. doi: 10.20524/aog.2019.0423. Epub 2019 Oct 8. Ann Gastroenterol. 2020. PMID: 31892804 Free PMC article.
Herein, we report 2 cases with rectal cancer that developed uncommon sites of metastasis; the first patient had an isolated breast metastasis, while the second patient developed bone marrow infiltration with synchronous brain metastases. ...
Herein, we report 2 cases with rectal cancer that developed uncommon sites of metastasis; the first patient had an isolated breast me …
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
Malorni L, Tyekucheva S, Hilbers FS, Ignatiadis M, Neven P, Colleoni M, Henry S, Ballestrero A, Bonetti A, Jerusalem G, Papadimitriou K, Bernardo A, Seles E, Duhoux FP, MacPherson IR, Thomson A, Davies DM, Bergqvist M, Migliaccio I, Gebhart G, Zoppoli G, Bliss JM, Benelli M, McCartney A, Kammler R, De Swert H, Ruepp B, Fumagalli D, Maibach R, Cameron D, Loi S, Piccart M, Regan MM; International Breast Cancer Study Group; Breast International Group and PYTHIA Collaborators. Malorni L, et al. Eur J Cancer. 2022 Mar;164:39-51. doi: 10.1016/j.ejca.2021.12.030. Epub 2022 Feb 13. Eur J Cancer. 2022. PMID: 35172272 Clinical Trial.
BACKGROUND: Biomarkers for cyclin-dependent kinase 4/6 inhibitors, such as palbociclib, for patients with hormone receptor-positive/HER2-negative metastatic breast cancer are lacking. Thymidine kinase is a proliferation marker downstream of the cyclin-dependent kinase 4/6 …
BACKGROUND: Biomarkers for cyclin-dependent kinase 4/6 inhibitors, such as palbociclib, for patients with hormone receptor-positive/HER2-neg …
Sushi domain-containing protein 4 binds to epithelial growth factor receptor and initiates autophagy in an EGFR phosphorylation independent manner.
Papadakos KS, Ekström A, Slipek P, Skourti E, Reid S, Pietras K, Blom AM. Papadakos KS, et al. J Exp Clin Cancer Res. 2022 Dec 29;41(1):363. doi: 10.1186/s13046-022-02565-1. J Exp Clin Cancer Res. 2022. PMID: 36578014 Free PMC article.
In vitro experiments utilized triple-negative breast cancer cell lines (BT-20 and MDA-MB-468) stably expressing SUSD4. ...RESULTS: We discovered that the Epithelial Growth Factor Receptor (EGFR) interacts with SUSD4. Furthermore, triple-negative breast cancer cell l …
In vitro experiments utilized triple-negative breast cancer cell lines (BT-20 and MDA-MB-468) stably expressing SUSD4. ...RESULTS: We …
Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period.
Matikas A, Kotsakis A, Perraki M, Hatzidaki D, Kalbakis K, Kontopodis E, Nikolaou M, Georgoulias V. Matikas A, et al. Breast Care (Basel). 2022 Jun;17(3):264-271. doi: 10.1159/000519729. Epub 2021 Oct 29. Breast Care (Basel). 2022. PMID: 35949417 Free PMC article.
INTRODUCTION: The purpose of this study was to study the efficacy of subsequent treatment lines for metastatic breast cancer (MBC), as well as the association between radiologic objective response rate (ORR) and overall survival (OS). ...
INTRODUCTION: The purpose of this study was to study the efficacy of subsequent treatment lines for metastatic breast cancer (MBC), a …
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.
Delaloge S, Piccart M, Rutgers E, Litière S, van 't Veer LJ, van den Berkmortel F, Brain E, Dudek-Peric A, Gil-Gil M, Gomez P, Hilbers FS, Khalil Z, Knox S, Kuemmel S, Kunz G, Lesur A, Pierga JY, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Thompson AM, Viale G, Zoppoli G, Vuylsteke P, Tryfonidis K, Poncet C, Bogaerts J, Cardoso F; MINDACT investigators and the TRANSBIG Consortium. Delaloge S, et al. J Clin Oncol. 2020 Apr 10;38(11):1186-1197. doi: 10.1200/JCO.19.01371. Epub 2020 Feb 21. J Clin Oncol. 2020. PMID: 32083990 Free PMC article. Clinical Trial.
PURPOSE: MINDACT demonstrated that 46% of patients with early breast cancer at high clinical but low genomic risk on the basis of MammaPrint may safely avoid adjuvant chemotherapy. ...
PURPOSE: MINDACT demonstrated that 46% of patients with early breast cancer at high clinical but low genomic risk on the basis of Mam …
A genome-wide pleiotropy scan for prostate cancer risk.
Panagiotou OA, Travis RC, Campa D, Berndt SI, Lindstrom S, Kraft P, Schumacher FR, Siddiq A, Papatheodorou SI, Stanford JL, Albanes D, Virtamo J, Weinstein SJ, Diver WR, Gapstur SM, Stevens VL, Boeing H, Bueno-de-Mesquita HB, Barricarte Gurrea A, Kaaks R, Khaw KT, Krogh V, Overvad K, Riboli E, Trichopoulos D, Giovannucci E, Stampfer M, Haiman C, Henderson B, Le Marchand L, Gaziano JM, Hunter DJ, Koutros S, Yeager M, Hoover RN; PRACTICAL Consortium; Chanock SJ, Wacholder S, Key TJ, Tsilidis KK. Panagiotou OA, et al. Eur Urol. 2015 Apr;67(4):649-57. doi: 10.1016/j.eururo.2014.09.020. Epub 2014 Sep 30. Eur Urol. 2015. PMID: 25277271 Free PMC article.
DESIGN, SETTING, AND PARTICIPANTS: SNPs implicated in any phenotype other than prostate cancer (p10(-7)) were identified through the catalog of published GWAS and tested in 2891 aggressive prostate cancer cases and 4592 controls from the Breast and Prostate Cancer Cohort C …
DESIGN, SETTING, AND PARTICIPANTS: SNPs implicated in any phenotype other than prostate cancer (p10(-7)) were identified through the catalog …
19 results